2025-01-29 10-40-59
Content
- A Urolithin A dose greater than 0.2 mg/kg may relieve pain from constriction of the Sciatic Nerve
References
| Assumptions2 | |
|---|---|
| 2025-01-28 21-05-34 | Intraperitoneal injection of Urolithin A in mice will result in higher bioavailability than an equivalent dose taken by mouth in humans |
| 2025-01-28 21-01-34 | Constriction of the Sciatic Nerve causes pain in similar ways in both mice and humans |
| Insights2 | |
|---|---|
| 2025-01-29 10-46-32 | Daily intraperitoneal injections of 2.5 mg/kg Urolithin A in mice reduce pain from chronic Sciatic Nerve constriction compared to mice not administered urolithin A |
| 2025-01-29 10-39-17 | A Urolithin A dose of 2.5 mg/kg/day in a mouse is equivalent to 0.2 mg/kg/day in a human |
| Original Sources2 | Citations |
|---|---|
| usfdaEstimatingMaximumSafe2018 | USFDA. “Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers.” FDA, December 1, 2018. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/estimating-maximum-safe-starting-dose-initial-clinical-trials-therapeutics-adult-healthy-volunteers. |
| wangUrolithinAlleviatesNeuropathic2023 | Wang, Chenyi, Zizhu Wang, Shiyu Xue, Yutong Zhu, Jiahao Jin, Qiuyu Ren, and Xiaodong Shi. “Urolithin A Alleviates Neuropathic Pain and Activates Mitophagy.” Molecular Pain 19 (July 28, 2023): 17448069231190815. https://doi.org/10.1177/17448069231190815. |